One company, Maryland-based Novavax, has now repurposed those vaccines for Sars-CoV-2, and says it has several candidates ready to enter human trials this spring.
Some of the Covid-19 vaccine projects are using these tried-and-tested approaches, but others are using newer technology.
As soon as a vaccine is approved, it’s going to be needed in vast quantities – and many of the organisations in the Covid-19 vaccine race simply don’t have the necessary production capacity.
– video explainerOnce a Covid-19 vaccine has been approved, a further set of challenges will present itself.
During the 2009 H1N1 flu pandemic, for example, vaccine supplies were snapped up by nations that could afford them, leaving poorer ones short.